Related Experiment Video
Updated: Jul 25, 2026
Assessing Functional Performance in the Mdx Mouse Model
Published on: March 27, 2014
Pre-clinical screening of drugs using the mdx mouse
J A Granchelli1, C Pollina, M S Hudecki
1Department of Biological Sciences, Box 601300, State University of New York at Buffalo, Buffalo, NY 14260-1300, USA.
Abstract:
The genetically dystrophin-deficient mdx mouse, with its characteristic and regular exercise-induced loss of strength, is a useful experimental platform on which to screen potential drug therapies in the treatment of some dystrophic diseases. Pharmacological agents of several chemical and functional classes were examined in their ability to reduce the loss of muscular strength in young exercised mdx mice. Therapeutic intervention over the period 4-10 weeks of age was evaluated in weekly tests of whole-body strength. This age period represents the most severe manifestation of disease in these animals. Significant improvements in whole-body strength were brought about by treatment with the immunosuppressive and anti-inflammatory drugs prednisone (at low dose only, 1 mg/kg body weight), pentoxifylline (100 mg/kg) and tinset (100 mg/kg). The anabolic hormone insulin-like growth factor-1 (5 mg/kg), as well as the amino acids/metabolites glutamine (10 mg/kg), glutamine plus alanine (each 10 mg/kg), and creatinine (10 mg/kg) all improved strength test performance. The mdx mouse is a responsive system for the screening of potential therapeutic treatments for the muscular dystrophies.
Insights
The mdx mouse model shows promise for testing muscular dystrophy drugs. Several compounds, including prednisone and insulin-like growth factor-1, improved muscle strength in young mice during peak disease.
Area of Science:
- Biomedical Science
- Pharmacology
- Genetics
Background:
- The dystrophin-deficient mdx mouse is a key model for studying muscular dystrophies.
- Exercise exacerbates muscle weakness in mdx mice, making it a relevant model for therapeutic screening.
Purpose of the Study:
- To evaluate the efficacy of various pharmacological agents in mitigating exercise-induced muscle weakness in mdx mice.
- To identify potential therapeutic candidates for muscular dystrophy treatment using the mdx mouse model.
Main Methods:
- mdx mice were treated with different pharmacological agents between 4 and 10 weeks of age.
- Whole-body strength was assessed weekly to monitor the effects of interventions.
- The study focused on the period of most severe disease manifestation in these animals.
Main Results:
- Low-dose prednisone (1 mg/kg), pentoxifylline (100 mg/kg), and tinset (100 mg/kg) significantly improved strength.
- Insulin-like growth factor-1 (5 mg/kg) also enhanced performance.
- Amino acids/metabolites including glutamine, glutamine plus alanine, and creatinine (each 10 mg/kg) demonstrated beneficial effects on strength.
Conclusions:
- The mdx mouse model is a responsive platform for screening potential treatments for muscular dystrophies.
- Several classes of drugs and compounds show potential for treating muscular dystrophy-related muscle weakness.
